Stock Events

Stock Events

Poolbeg Pharma 

$0.095800
41
+$0.00+0.84%Friday 20:00

Statistics

Day High
0.095
Day Low
0.095
52W High
0.1154
52W Low
0.0425
Volume
10,000
Avg. Volume
238
Mkt Cap
67.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Sep 29Expected
Q1 2024
Q2 2024
Q4 2024
Q1 2025
Q2 2025
Q1 2026
Q2 2026
-0.01
-0.01
-0
-0
Expected EPS
-0.00371196
Actual EPS
-0.00371196

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
2025
0Revenue
-7.72MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow POLBF. It's not an investment recommendation.
Legal & General Group
8
LGEN.LSE
Lloyds Banking Group
7
LLOY.LSE
hVIVO.
6
HVO.LSE
Aviva
5
AV.LSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap88.52B
Moderna is a leader in mRNA technology, competing in the infectious disease space with innovative vaccine developments, similar to Poolbeg's focus on infectious disease treatments.
BioNTech
BNTX
Mkt Cap22.15B
BioNTech, known for its COVID-19 vaccine, competes in the infectious disease arena, leveraging mRNA technology which overlaps with Poolbeg's research interests.
Novavax
NVAX
Mkt Cap1.66B
Novavax is a competitor due to its work on vaccines for infectious diseases, directly competing with Poolbeg Pharma's focus area.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is involved in the development of antiviral drugs, directly competing with Poolbeg Pharma's focus on infectious disease treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals competes with Poolbeg Pharma through its development of treatments for infectious diseases, including its work on antibodies.
Pfizer
PFE
Mkt Cap173.95B
Pfizer is a global pharmaceutical company with a broad infectious disease portfolio, making it a competitor to Poolbeg Pharma.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops treatments for infectious diseases, competing with Poolbeg Pharma.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca is involved in developing vaccines and treatments for infectious diseases, positioning it as a competitor to Poolbeg Pharma.
Sanofi
SNY
Mkt Cap106.24B
Sanofi is focused on creating vaccines and treatments for infectious diseases, making it a direct competitor to Poolbeg Pharma.
Merck
MRK
Mkt Cap368.89B
Merck & Co. is known for its strong portfolio in infectious disease treatments, including vaccines and antiviral drugs, competing with Poolbeg Pharma.

About

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Show More
CEO
Jeremy Skillington
Employees
15
Country
United Kingdom
ISIN
GB00BKPG7Z60
WKN
000A3CVN5

Listings

STU
DE
7JN.STU
F
DE
7JN.F
LSE
GB
POLB.LSE
OTC Link
US
POLBF

0 Comments

Share your thoughts

FAQs

What is Poolbeg Pharma stock price today?▼
The current price of POLBF is $0.10 USD — it has increased by +0.84% in the past 24 hours. Watch Poolbeg Pharma stock price performance more closely on the chart.
What is Poolbeg Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Poolbeg Pharma stocks are traded under the ticker POLBF.
Is Poolbeg Pharma stock price growing?▼
POLBF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Poolbeg Pharma has showed a +125.41% increase.
What is Poolbeg Pharma market cap?▼
Today Poolbeg Pharma has the market capitalization of 67.55M
When is the next Poolbeg Pharma earnings date?▼
Poolbeg Pharma is going to release the next earnings report on March 4, 2027.
What were Poolbeg Pharma earnings last quarter?▼
POLBF earnings for the last quarter are -0 USD per share, whereas the estimation was -0 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Poolbeg Pharma revenue for the last year?▼
Poolbeg Pharma revenue for the last year amounts to 0 USD.
What is Poolbeg Pharma net income for the last year?▼
POLBF net income for the last year is -7.72M USD.
How many employees does Poolbeg Pharma have?▼
As of November 8, 2026, the company has 15 employees.
In which sector is Poolbeg Pharma located?▼
Poolbeg Pharma operates in the Health & Wellness sector.
When did Poolbeg Pharma complete a stock split?▼
Poolbeg Pharma has not had any recent stock splits.
Where is Poolbeg Pharma headquartered?▼
Poolbeg Pharma is headquartered in London, United Kingdom.